Patients with cardiac gene mutations have increased rates of neurological disorders: high rates of epilepsy in patients with LQT2 syndrome due to KCNH2 mutations (66) and high rates of neurodevelopmental delay in patients with CPVT due to RYR2 mutations (67). The gene discussed is KCNH2; the disease is catecholaminergic polymorphic ventricular tachycardia.